Amylyx Pharmaceuticals, Inc. $AMLX Shares Bought by Commodore Capital LP

Commodore Capital LP lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 38.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,650,000 shares of the company’s stock after acquiring an additional 1,574,522 shares during the period. Amylyx Pharmaceuticals makes up about 4.5% of Commodore Capital LP’s portfolio, making the stock its 9th largest holding. Commodore Capital LP owned approximately 0.05% of Amylyx Pharmaceuticals worth $68,252,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $25,000. California State Teachers Retirement System bought a new stake in Amylyx Pharmaceuticals during the second quarter worth $28,000. Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. BNP Paribas Financial Markets boosted its holdings in shares of Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $48,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on AMLX shares. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. Guggenheim boosted their target price on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Mizuho raised their price target on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. Finally, Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Amylyx Pharmaceuticals Stock Up 1.3%

NASDAQ AMLX opened at $15.25 on Thursday. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -10.17 and a beta of -0.16. Amylyx Pharmaceuticals, Inc. has a twelve month low of $4.80 and a twelve month high of $18.60. The business’s fifty day moving average is $15.15 and its 200 day moving average is $14.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.4 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.